Detecting Recurrent Prostate Cancer With 11C-choline Positron Emission Tomography
Description
The purpose of this study is to use a new imaging drug called 11C-choline that is used with a PET/CT scan to see prostate cancer when it cannot be seen well on other scans, such as bone scans, CT or MRI.
Study Start Date
August 2015
Estimated Completion Date
August 2019
Interventions
- Device: PET/CT Scan
- Drug: 11C-choline
Specialties
- Internal Medicine: Hematology/Oncology,Men’s Health,Nephrology/Urology
- Urology: Oncology,Prostate
- Family Medicine: Men`s Health,Urology
- Oncology: Renal/Urologic
- Physician Assistant: Hematology/Oncology,Urology
MeSH Terms
- Positron Emission Tomography
- Prostate Cancer
Study ID
Memorial Sloan Kettering Cancer Center -- 15-117
Status
Available
Trial ID
Study Type
Expanded Access
Trial Phase
N/A
Enrollment Quota
Not Listed
Sponsor
Memorial Sloan Kettering Cancer Center
Inclusion Criteria
- Patient must have biopsy-proven adenocarcinoma of the prostate initially treated with curative intent (surgery and radiation therapy are most common treatments but other treatments are also eligible).
- Biochemical recurrence defined as any of the following: 1. PSA ? 0.2 ng/mL in at least two sequential tests for patients treated with surgery. 2. PSA ? 0.2 ng/mL above the post therapy nadir for patients treated with radiation therapy, brachytherapy or cryotherapy. 3. PSA ? 0.2 ng/ml above the most recent therapy nadir for patients who have received additional treatment in the recurrent setting
- Patient must have undergone standard-of-care restaging that does not clearly identify site(s) of active disease, or such prior studies must show equivocal findings for which further work-up is considered necessary to make clinical decision. Standard staging examinations may include one or more of the following: CT or MRI, bone imaging (either Tc-99m bisphosphonate scintigraphy MDP or F-18 sodium fluoride PET), or In-111 capromab pendetide scintigraphy no older than 3 months.
- Age ? 18 years.
- Patient must be able to tolerate PET/CT imaging.
- Patient must be able to understand and willing to sign a written informed consent document.
Exclusion Criteria
- Patient must not have claustrophobia that would preclude PET/CT imaging or other contraindications to CT imaging.
Gender
Male
Ages
18 Years and older
Accepts Healthy Volunteers
No
Study Locations and Contact Information (1)
Study Location | Distance | Name | Phone | |
---|---|---|---|---|
Memorioal Sloan Kettering Cancer Center - New York, New York | 50.7 miles | Heiko Schoder MD | 212-639-2079 | None |